相关实验视频
Updated: Sep 14, 2025

08:39
A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
1.8K
运动在减轻血液透析患者症状负担方面的有效性:一种非药物干预方法
Bushra Alshammari1, J Silvia Edison1, Sameer A Alkubati1
1Medical Surgical Nursing Department, College of Nursing, University of Hail, Hail, Saudi Arabia.
Frontiers in public health
|July 24, 2025
概括
结构化的运动显著减少了血液透析 (HD) 患者的症状负担. 这种非药物治疗方法改善了身体和情绪的健康,支持将运动纳入常规的HD护理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 运动生理学 运动生理学
- 患者的生活质量.
背景情况:
- 接受血液透析 (HD) 的末期病 (ESRD) 患者经历了显著的症状负担,影响了生活质量.
- 像运动这样的非药物干预措施为HD患者管理各种症状提供了有希望的药物替代方案.
研究的目的:
- 评估结构化炼干预措施在减轻沙特阿拉伯血液透析患者症状负担方面的有效性.
主要方法:
- 在72名HD患者中使用了准实验性的前后研究设计.
- 参与者接受了为期12周的结构化炼计划 (每周3次,每次30分钟).
- 使用透析症状指数 (DSI) 测量症状严重程度,包括干预前和干预后.
主要成果:
- 运动干预导致整体症状严重程度的统计显著降低 (p < 0.001).
- 在包括便秘,食欲,腿部不安,疲劳,关节疼痛,集中力和情绪健康在内的特定症状中观察到显著改善.
- 年轻的年龄,女性性别,更短的透析持续时间和更高的并发症与更大的基线症状严重程度有关.
结论:
- 一个结构化的炼计划有效地减少了血液透析患者的症状负担.
- 运动应纳入常规的HD护理,以提高患者的幸福感.
- 透析中心的监督,可访问的运动计划可以最大限度地提高治疗效益和治疗效益.
相关概念视频
Hemodialysis III: Nursing Management
189
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
189
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Hemodialysis II: Procedure and Complications
137
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
137
Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510

